GSK PHARMA – Broad overview –
No 1 in India in – vaccines, anti-infectives derma therapies
Has 4 brands in top 50 branded generics in India. These are – Calpol (PCM), Augumentin (amoxycillin), T-Bact ( topical cream for bacterial skin infections ) and Ceftum ( Cefuroxime – a second Gen Cephalosporin ). Company launched brand extensions of two of these brands – Calpol 650+ and Augmentin ES in 2023. Eltroxin( for hyperthyroidism ), CCM ( Vit D supplement ), Neosporin ( topical cream for bacterial skin infections ), Betnovate ( anti-inflammatory skin cream ) are other popular brands from GSK
05 of GSK’s vaccines are ranked among top 15 vaccines brands in India. Have launched an adult vaccine in India to prevent – Shingles – in FY 23
In 2024, GSK will complete 100 yrs in India
Company also owns 02 popular speciality brands in India – Nucala ( only biologic treatment for eosinophilic asthma ) and Trelegy ( to treat obstructive pulmonary disease )
FY 23 financials –
Sales – 3216 vs 3218 cr
EBITDA – 800 vs 755 cr (margins @ 25 vs 23 pc)
PAT – 605 vs 552 cr
Current Size of IPM @ $52 billion. Expected to cross $ 100 billion by 2030
Company’s formulations facility is located at Maharashtra. Company has 22 Contract manufacturing partners in India
Disc: hold a tracking position, not SEBI registered, biased
| Subscribe To Our Free Newsletter |
